AVTX
Avalo Therapeutics, Inc.
+0.14 (+0.84%)16.72USD210K成交股數897M市值–本益比(近四季)15198.2股價營收比–營收年增(近四季)2026-11-12下次財報
內部人交易 SEC Form 4 · 董事、高階主管與持股 10% 以上股東 · 交易後兩個營業日內申報
買賣點與股價近一年
● 公開市場買進 · ● 公開市場賣出 · 空心 = 10b5-1 預設計畫(事先排程,不代表當下看法)。近一年,只畫 P / S 兩種代碼。
統計
| 近 90 天 買進筆數 · 金額 · 人數 | 0 · 0.00 · 0 |
|---|---|
| 近 90 天 賣出筆數 · 金額 · 人數 | 11 · 1.9M · 3 |
| 其中 10b5-1 計畫賣出 | 10 筆 |
| 近 180 天 買進 · 賣出金額 | 0.00 · 7.7M |
| 近 180 天 淨額 | −7.7M |
公開市場買進(P)是內部人自掏腰包,通常比賣出更有資訊含量 —— 賣出的理由很多(繳稅、分散、買房),買進的理由只有一個。
10b5-1 是事先排定的交易計畫,執行時點不反映當下看法。獲配股票(A)、繳稅扣股(F)、選擇權執行(M)是薪酬流程,不是意見。
| 交易日 | 申報日 | 申報人 | 職稱 | 代碼 | 股數 | 價格 | 金額 | 交易後持股 | 原件 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-10 | 09-11 | Sullivan Christopher Ryan | Chief Financial Officer | S 公開市場賣出(10b5-1) | 10.2K | 17.62 | 179K | 39.9K | SEC |
| 2026-09-10 | 09-11 | Sullivan Christopher Ryan | Chief Financial Officer | M 選擇權執行 | 10.2K | 8.04 | 82K | 50.1K | SEC |
| 2026-08-28 | 09-01 | Doyle Mittie | Chief Medical Officer | S 公開市場賣出(10b5-1) | 679 | 20.00 | 14K | 51.8K | SEC |
| 2026-08-28 | 09-01 | Doyle Mittie | Chief Medical Officer | M 選擇權執行 | 679 | 8.04 | 5K | 52.5K | SEC |
| 2026-08-18 | 08-19 | Sullivan Christopher Ryan | Chief Financial Officer | S 公開市場賣出(10b5-1) | 31.0K | 20.05 | 622K | 39.9K | SEC |
| 2026-08-18 | 08-19 | Sullivan Christopher Ryan | Chief Financial Officer | M 選擇權執行 | 31.0K | 9.88 | 307K | 70.9K | SEC |
| 2026-08-17 | 08-19 | Sullivan Christopher Ryan | Chief Financial Officer | S 公開市場賣出(10b5-1) | 3.7K | 19.94 | 75K | 39.9K | SEC |
| 2026-08-17 | 08-19 | Sullivan Christopher Ryan | Chief Financial Officer | M 選擇權執行 | 37.9K | 9.88 | 375K | 78.7K | SEC |
| 2026-08-17 | 08-19 | Sullivan Christopher Ryan | Chief Financial Officer | S 公開市場賣出(10b5-1) | 37.9K | 19.85 | 753K | 43.6K | SEC |
| 2026-08-17 | 08-19 | Sullivan Christopher Ryan | Chief Financial Officer | M 選擇權執行 | 2.9K | 9.88 | 28K | 81.6K | SEC |
| 2026-08-17 | 08-19 | Doyle Mittie | Chief Medical Officer | S 公開市場賣出(10b5-1) | 1.0K | 20.00 | 20K | 51.8K | SEC |
| 2026-08-17 | 08-19 | Doyle Mittie | Chief Medical Officer | M 選擇權執行 | 1.0K | 12.65 | 13K | 52.8K | SEC |
| 2026-08-11 | 08-12 | Riley Jennifer | Chief Strategy Officer | S 公開市場賣出 | 2.7K | 19.59 | 52K | 37.0K | SEC |
| 2026-08-10 | 08-12 | Doyle Mittie | Chief Medical Officer | S 公開市場賣出(10b5-1) | 679 | 20.00 | 14K | 51.8K | SEC |
| 2026-08-10 | 08-12 | Doyle Mittie | Chief Medical Officer | M 選擇權執行 | 679 | 8.04 | 5K | 52.5K | SEC |
| 2026-07-27 | 07-29 | Doyle Mittie | Chief Medical Officer | S 公開市場賣出(10b5-1) | 1.0K | 20.00 | 20K | 51.8K | SEC |
| 2026-07-27 | 07-29 | Doyle Mittie | Chief Medical Officer | M 選擇權執行 | 1.0K | 12.65 | 13K | 52.8K | SEC |
| 2026-06-30 | 07-02 | Doyle Mittie | Chief Medical Officer | S 公開市場賣出(10b5-1) | 4.7K | 20.00 | 93K | 51.8K | SEC |
| 2026-06-30 | 07-02 | Doyle Mittie | Chief Medical Officer | M 選擇權執行 | 1.8K | 8.04 | 14K | 56.4K | SEC |
| 2026-06-30 | 07-02 | Doyle Mittie | Chief Medical Officer | M 選擇權執行 | 2.9K | 12.65 | 36K | 54.7K | SEC |
| 2026-06-23 | 06-25 | Doyle Mittie | Chief Medical Officer | S 公開市場賣出(10b5-1) | 1.4K | 18.00 | 26K | 51.8K | SEC |
| 2026-06-23 | 06-25 | Doyle Mittie | Chief Medical Officer | M 選擇權執行 | 1.4K | 8.04 | 12K | 53.2K | SEC |
| 2026-06-10 | 06-12 | Sullivan Christopher Ryan | Chief Financial Officer | F 繳稅扣股 | 138 | 13.10 | 2K | 40.8K | SEC |
| 2026-06-10 | 06-12 | Riley Jennifer | Chief Strategy Officer | F 繳稅扣股 | 588 | 13.10 | 8K | 39.7K | SEC |
| 2026-06-10 | 06-12 | Doyle Mittie | Chief Medical Officer | F 繳稅扣股 | 1.1K | 13.10 | 14K | 51.8K | SEC |
| 2026-06-10 | 06-12 | VARKI PAUL | Chief Legal Officer | F 繳稅扣股 | 1.1K | 13.10 | 14K | 32.6K | SEC |
| 2026-05-28 | 06-01 | Doyle Mittie | Chief Medical Officer | S 公開市場賣出(10b5-1) | 679 | 16.00 | 11K | 47.1K | SEC |
| 2026-05-28 | 06-01 | Doyle Mittie | Chief Medical Officer | M 選擇權執行 | 679 | 8.04 | 5K | 47.8K | SEC |
| 2026-05-21 | 05-26 | Sullivan Christopher Ryan | Chief Financial Officer | A 獲配股票 | 39.9K | – | – | 40.3K | SEC |
| 2026-05-21 | 05-26 | VARKI PAUL | Chief Legal Officer | A 獲配股票 | 24.3K | – | – | 27.9K | SEC |
| 2026-05-21 | 05-26 | NEIL GARRY ARTHUR | Chief Executive Officer | A 獲配股票 | 100K | – | – | 190K | SEC |
| 2026-05-21 | 05-26 | Riley Jennifer | Chief Strategy Officer | A 獲配股票 | 34.2K | – | – | 36.9K | SEC |
| 2026-05-21 | 05-26 | Doyle Mittie | Chief Medical Officer | A 獲配股票 | 43.5K | – | – | 47.1K | SEC |
| 2026-05-15 | 05-19 | Doyle Mittie | Chief Medical Officer | S 公開市場賣出(10b5-1) | 3.0K | 18.76 | 56K | 3.6K | SEC |
| 2026-05-15 | 05-19 | Doyle Mittie | Chief Medical Officer | M 選擇權執行 | 3.0K | 12.65 | 38K | 6.6K | SEC |
| 2026-05-07 | 05-11 | Sullivan Christopher Ryan | Chief Financial Officer | S 公開市場賣出(10b5-1) | 18.6K | 24.12 | 449K | 423 | SEC |
| 2026-05-07 | 05-11 | Sullivan Christopher Ryan | Chief Financial Officer | M 選擇權執行 | 18.6K | 9.88 | 184K | 19.0K | SEC |
| 2026-05-06 | 05-07 | Doyle Mittie | Chief Medical Officer | M 選擇權執行 | 28.6K | 8.04 | 230K | 110K | SEC |
| 2026-05-06 | 05-07 | Doyle Mittie | Chief Medical Officer | S 公開市場賣出(10b5-1) | 10.1K | 22.88 | 230K | 3.6K | SEC |
| 2026-05-06 | 05-07 | Doyle Mittie | Chief Medical Officer | S 公開市場賣出(10b5-1) | 44.9K | 21.20 | 953K | 32.7K | SEC |
| 2026-05-06 | 05-07 | Doyle Mittie | Chief Medical Officer | S 公開市場賣出(10b5-1) | 5.0K | 19.65 | 98K | 77.6K | SEC |
| 2026-05-06 | 05-07 | Doyle Mittie | Chief Medical Officer | S 公開市場賣出(10b5-1) | 27.5K | 18.03 | 497K | 82.6K | SEC |
| 2026-05-06 | 05-07 | Sullivan Christopher Ryan | Chief Financial Officer | S 公開市場賣出(10b5-1) | 12.3K | 19.28 | 238K | 21.2K | SEC |
| 2026-05-06 | 05-07 | Sullivan Christopher Ryan | Chief Financial Officer | S 公開市場賣出(10b5-1) | 2.7K | 20.76 | 56K | 18.5K | SEC |
| 2026-05-06 | 05-07 | VARKI PAUL | Chief Legal Officer | M 選擇權執行 | 62.5K | 13.43 | 839K | 66.1K | SEC |
| 2026-05-06 | 05-07 | Sullivan Christopher Ryan | Chief Financial Officer | S 公開市場賣出(10b5-1) | 8.9K | 22.57 | 201K | 423 | SEC |
| 2026-05-06 | 05-07 | Sullivan Christopher Ryan | Chief Financial Officer | S 公開市場賣出(10b5-1) | 9.2K | 21.37 | 197K | 9.3K | SEC |
| 2026-05-06 | 05-07 | Doyle Mittie | Chief Medical Officer | S 公開市場賣出(10b5-1) | 19.0K | 22.41 | 426K | 13.7K | SEC |
| 2026-05-06 | 05-07 | Sullivan Christopher Ryan | Chief Financial Officer | S 公開市場賣出(10b5-1) | 13.8K | 18.55 | 257K | 33.6K | SEC |
| 2026-05-06 | 05-07 | Sullivan Christopher Ryan | Chief Financial Officer | M 選擇權執行 | 47.0K | 8.04 | 378K | 47.4K | SEC |
| 2026-05-06 | 05-07 | Chan Mitchell | Director | S 公開市場賣出(10b5-1) | 3.2K | 22.88 | 72K | 3.2K | SEC |
| 2026-05-06 | 05-07 | VARKI PAUL | Chief Legal Officer | S 公開市場賣出(10b5-1) | 400 | 23.71 | 9K | 3.6K | SEC |
| 2026-05-06 | 05-07 | VARKI PAUL | Chief Legal Officer | S 公開市場賣出(10b5-1) | 9.3K | 22.70 | 210K | 4.0K | SEC |
| 2026-05-06 | 05-07 | Doyle Mittie | Chief Medical Officer | M 選擇權執行 | 77.9K | 12.65 | 985K | 81.5K | SEC |
| 2026-05-06 | 05-07 | VARKI PAUL | Chief Legal Officer | S 公開市場賣出(10b5-1) | 22.8K | 21.22 | 485K | 13.3K | SEC |
| 2026-05-06 | 05-07 | VARKI PAUL | Chief Legal Officer | S 公開市場賣出(10b5-1) | 5.2K | 19.78 | 103K | 36.1K | SEC |
| 2026-05-06 | 05-07 | VARKI PAUL | Chief Legal Officer | S 公開市場賣出(10b5-1) | 37.4K | 18.91 | 707K | 41.3K | SEC |
| 2026-05-06 | 05-07 | VARKI PAUL | Chief Legal Officer | M 選擇權執行 | 12.6K | 8.04 | 101K | 78.7K | SEC |
| 2026-05-05 | 05-07 | Doyle Mittie | Chief Medical Officer | M 選擇權執行 | 679 | 8.04 | 5K | 5.3K | SEC |
| 2026-05-05 | 05-07 | Doyle Mittie | Chief Medical Officer | M 選擇權執行 | 1.0K | 12.65 | 13K | 4.6K | SEC |
| 2026-05-05 | 05-07 | Doyle Mittie | Chief Medical Officer | S 公開市場賣出(10b5-1) | 1.7K | 16.00 | 27K | 3.6K | SEC |
| 2026-04-30 | 05-01 | Sullivan Christopher Ryan | Chief Financial Officer | S 公開市場賣出(10b5-1) | 8.5K | 13.23 | 112K | 423 | SEC |
| 2026-04-29 | 05-01 | Sullivan Christopher Ryan | Chief Financial Officer | S 公開市場賣出(10b5-1) | 8.5K | 13.09 | 111K | 8.9K | SEC |
| 2026-04-06 | 04-08 | Doyle Mittie | Chief Medical Officer | M 選擇權執行 | 4.0K | 12.65 | 50K | 7.6K | SEC |
| 2026-04-06 | 04-08 | Doyle Mittie | Chief Medical Officer | S 公開市場賣出(10b5-1) | 4.0K | 18.01 | 71K | 3.6K | SEC |
| 2026-04-02 | 04-03 | Sullivan Christopher Ryan | Chief Financial Officer | S 公開市場賣出(10b5-1) | 1.8K | 17.57 | 31K | 17.3K | SEC |
| 2026-04-02 | 04-03 | Sullivan Christopher Ryan | Chief Financial Officer | S 公開市場賣出(10b5-1) | 6.2K | 17.02 | 106K | 19.1K | SEC |
| 2026-04-01 | 04-03 | Doyle Mittie | Chief Medical Officer | M 選擇權執行 | 679 | 8.04 | 5K | 4.3K | SEC |
| 2026-04-01 | 04-03 | Sullivan Christopher Ryan | Chief Financial Officer | S 公開市場賣出(10b5-1) | 7.5K | 16.83 | 126K | 25.3K | SEC |
| 2026-04-01 | 04-03 | Sullivan Christopher Ryan | Chief Financial Officer | S 公開市場賣出(10b5-1) | 500 | 15.86 | 8K | 32.8K | SEC |
| 2026-04-01 | 04-03 | Doyle Mittie | Chief Medical Officer | S 公開市場賣出(10b5-1) | 679 | 16.00 | 11K | 3.6K | SEC |
| 2026-03-28 | 03-31 | Truex Samantha | Director | M 選擇權執行 | 3.2K | – | – | 6.3K | SEC |
| 2026-03-28 | 03-31 | KANTOFF AARON | Director | M 選擇權執行 | 3.2K | – | – | 6.3K | SEC |
| 2026-03-28 | 03-31 | Sullivan Christopher Ryan | Chief Financial Officer | F 繳稅扣股 | 8.2K | 13.89 | 114K | 33.3K | SEC |
| 2026-03-28 | 03-31 | Sullivan Christopher Ryan | Chief Financial Officer | M 選擇權執行 | 24.2K | – | – | 41.5K | SEC |
| 2026-03-28 | 03-31 | Chan Mitchell | Director | M 選擇權執行 | 3.2K | – | – | 6.3K | SEC |
| 2026-03-28 | 03-31 | NEIL GARRY ARTHUR | Chief Executive Officer | F 繳稅扣股 | 21.9K | 13.89 | 304K | 90.1K | SEC |
| 2026-03-28 | 03-31 | Goldman Jonathan | Director | M 選擇權執行 | 3.2K | – | – | 3.2K | SEC |
| 2026-03-28 | 03-31 | NEIL GARRY ARTHUR | Chief Executive Officer | M 選擇權執行 | 64.9K | – | – | 112K | SEC |
| 2026-03-28 | 03-31 | KAPLAN GILLA | Director | M 選擇權執行 | 3.2K | – | – | 6.3K | SEC |
機構持股(13F) 管理規模 1 億美元以上的機構,每季末後 45 天內申報 · 最新 2026-06-30
前 25 大持有機構季末市值 · 與前一季股數比較
| 機構 | 持股 | 季末市值 | 股數季變化 | 動作 |
|---|---|---|---|---|
| FMR LLC | 5.1M | 94.3M | 新進 | 新進 |
| BlackRock, Inc. | 4.4M | 80.7M | 新進 | 新進 |
| Nantahala Capital Management, LLC | 3.7M | 68.8M | 新進 | 新進 |
| Deep Track Capital, LP | 3.6M | 66.7M | 新進 | 新進 |
| Caligan Partners LP | 3.2M | 58.5M | 新進 | 新進 |
| TCG Crossover Management, LLC | 3.0M | 55.8M | 新進 | 新進 |
| Affinity Asset Advisors, LLC | 2.9M | 53.6M | 新進 | 新進 |
| STATE STREET CORP | 2.9M | 53.4M | 新進 | 新進 |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 2.5M | 46.2M | 新進 | 新進 |
| Point72(柯恩) Point72 Asset Management, L.P. | 2.4M | 44.1M | 新進 | 新進 |
| Avoro Capital Advisors LLC | 2.3M | 43.1M | 新進 | 新進 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.3M | 41.8M | 新進 | 新進 |
| BVF INC/IL | 2.1M | 38.4M | 新進 | 新進 |
| BANK OF AMERICA CORP /DE/ | 1.9M | 35.4M | 新進 | 新進 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.7M | 32.0M | 新進 | 新進 |
| Soleus Capital Management, L.P. | 1.7M | 30.6M | 新進 | 新進 |
| BRAIDWELL LP | 1.6M | 30.1M | 新進 | 新進 |
| ALLIANCEBERNSTEIN L.P. | 1.3M | 23.3M | 新進 | 新進 |
| UBS Group AG | 1.2M | 22.3M | 新進 | 新進 |
| Logos Global Management LP | 1.1M | 21.3M | 新進 | 新進 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.1M | 20.4M | 新進 | 新進 |
| Commodore Capital LP | 1.0M | 18.8M | 新進 | 新進 |
| RA CAPITAL MANAGEMENT, L.P. | 1.0M | 18.5M | 新進 | 新進 |
| GOLDMAN SACHS GROUP INC | 946K | 17.5M | 新進 | 新進 |
| Trails Edge Capital Partners, LP | 892K | 16.5M | 新進 | 新進 |
持有機構數近 12 季
每季 13F 申報中持有本股的機構家數;綠柱 = 比上季少。機構數是「有多少人在船上」,不是「買了多少」。
| 持有機構 · 季變化 | 126 +29 |
|---|---|
| 新進 / 出清 / 加碼 / 減碼 | 126 / 0 / 0 / 0 |
| 機構合計持股 · 佔流通股 | 72.6M · 100.0% |
| 合計季末市值 | 1.3B |
13F 只申報多頭部位(含可轉債與選擇權,選擇權這裡已排除),不申報放空,也不申報 1 億美元以下的機構。同一集團多個申報主體會各算一家。
放空餘額 FINRA 每月兩次(15 日與月底結算)· 最新 2026-08-31
空單佔流通股近 13 個月
FINRA 每月兩次結算的空單餘額佔流通股數的比例,近 13 個月。滑到柱子看股數與回補天數。
最新一期
| 空單股數 | 12.4M |
|---|---|
| 與上期比 | -5.4% |
| 佔流通股數 | 23.10% |
| 日均成交量 | 817K |
| 回補天數 | 15.2 天 |
空單佔比 10% 以上算高、20% 以上算很高(這是通行的說法,不是本站的判斷)。回補天數 = 空單 ÷ 日均量,天數愈長,空方要出場時愈容易推升股價。
放空餘額是「有人借股票賣掉還沒還」的存量,不代表看空的人正在加碼;避險基金做多空配對時也會產生空單。
| 結算日 | 空單股數 | 與上期比 | 佔流通股 | 日均量 | 回補天數 |
|---|---|---|---|---|---|
| 2026-08-31 | 12.4M | -5.4% | 23.10% | 817K | 15.2 |
| 2026-08-14 | 13.1M | +1.1% | 24.41% | 647K | 20.2 |
| 2026-07-31 | 13.0M | +2.1% | 24.15% | 900K | 14.4 |
| 2026-07-15 | 12.7M | +3.0% | 23.64% | 1.2M | 10.7 |
| 2026-06-30 | 12.3M | +66.0% | 22.95% | 2.9M | 4.3 |
| 2026-06-15 | 7.4M | +16.2% | 13.82% | 1.3M | 5.5 |
| 2026-05-29 | 6.4M | +2.0% | 11.90% | 1.5M | 4.4 |
| 2026-05-15 | 6.3M | +9.1% | 11.66% | 3.9M | 1.6 |
| 2026-04-30 | 5.7M | +9.5% | 10.69% | 708K | 8.1 |
| 2026-04-15 | 5.2M | -5.5% | 9.77% | 855K | 6.1 |
| 2026-03-31 | 5.5M | +35.5% | 10.33% | 893K | 6.2 |
| 2026-03-13 | 4.1M | +11.1% | 7.62% | 702K | 5.8 |
| 2026-02-27 | 3.7M | +2.4% | 6.87% | 511K | 7.2 |
| 2026-02-13 | 3.6M | +13.0% | 6.71% | 381K | 9.4 |
| 2026-01-30 | 3.2M | +6.8% | 5.94% | 392K | 8.1 |
| 2026-01-15 | 3.0M | +16.0% | 5.56% | 293K | 10.2 |
| 2025-12-31 | 2.6M | +38.2% | 4.79% | 340K | 7.6 |
| 2025-12-15 | 1.9M | +0.5% | 3.47% | 312K | 6.0 |
| 2025-11-28 | 1.8M | +0.5% | 3.45% | 354K | 5.2 |
| 2025-11-14 | 1.8M | +36.8% | 3.43% | 380K | 4.8 |
| 2025-10-31 | 1.3M | +3.3% | 2.51% | 412K | 3.3 |
| 2025-10-15 | 1.3M | +4.8% | 2.43% | 322K | 4.0 |
| 2025-09-30 | 1.2M | +513.9% | 2.32% | 619K | 2.0 |
| 2025-09-15 | 202K | +263.9% | 0.38% | 205K | 1.0 |
| 2025-08-29 | 55.6K | -38.4% | 0.10% | 130K | 1.0 |
| 2025-08-15 | 90.2K | +117.5% | 0.17% | 457K | 1.0 |